肝动脉化疗栓塞术(TACE)治疗中晚期肝癌77例临床疗效分析

Therapeutic Effect of Transcatheter Arterial Chemoembolization(TACE)on Mid-advanced Primary Liver Carcinoma(PLC):a Report of 77 Cases

目的分析TACE中晚期肝癌的临床疗效.方法采用肝叶或肝段动脉插管化疗加栓塞(TACE)治疗77例中晚期肝癌并分析临床效果.结果行TACE 77例,平均栓塞(2.7±1.8)次/人,其显效率、部分显效率和无效率分别为40.3%(31/77)、48.1%(37/77)和11.6%.单行化疗灌注12例,平均灌注(1.8±1.1)次/人,显效率、部分显效率和无效率分别为:16.7%(2/12)、25.0%(3/12)和58.3%.随访22.3个月,小于6个月生存率为64%(57/89),6～12个月生存率为18.0%(16/89)、13～18个月生存率为11.2%(10/89)、超过18个月生存率为6.7%(6/89).全组无严重并发症.结论 TACE治疗中晚期肝癌安全可靠,其临床疗效优于单独行灌注者.因此在严格适应症的基础上,应尽量采用高选择性肝动脉灌注化疗加栓塞提高中晚期肝癌治疗效果.

Objective To investigate the effect of transcatheter arterial chemoembolization （TACE） on Mid-advanced primary liver carcinoma （PLC）. Method 77 patients suffered from mid-advanced suffered were treated with TACE, and the clinical effect was investigated and evaluated. Results 89cases were performed with Hepatic artery intubation successfully, and 77 cases were treated with TACE. （2.7 _＋ 1.8） times/case were performed successfully in the 77 cases. The efficiency, some efficiency and inefficiency were 40.3% （31/77） , 48.1% （37/77） and l 1.6% , respectively. Other 12 cases were performed only with hepatic arterial infusion chemotherapy, and the efficiency, some efficiency and inefficiency were16.7% （2/12） , 25.0% （3/12） and 58.3%, respectively. Patients were followed up for 22.3 months, and the patients＇ survival rate in less than 6 months, 6-12 months, 13-18 months and longer than 18 months were 64% （57/89） , 18.0% （16/89） 11.2% （10/89） and 6.7% （6/89）. No severe complications were found in the 77 cases. Conclusion Transcatheter arterial chemoembolization （TACE） is reliable and feasible in treating mid-advanced primary liver carcinoma （PLC） , and TACE maybe bring more benefits to patients suffered from mid-advanced primary liver carcinoma.